AU
UK
CA
US
IND
NZ
Company Overview
Caris Life Sciences (CAI), a leading AI TechBio and precision medicine pioneer founded in 2008, has solidified its position in oncology by leveraging comprehensive molecular profiling and AI/ML technologies, amassing one of the largest multi-modal clinico-genomic datasets with over 6.5 million tests on 849,000 cases, generating 38 billion molecular markers, and serving clinical, academic, and biopharma markets with solutions like MI Profile and the Q1 2024-launched Caris Assure, as of March 31, 2025. The company’s platform, utilizing whole exome sequencing (WES) and whole transcriptome sequencing (WTS) on every eligible sample—over 500,000 cases since 2019—achieves industry-leading sequencing depths (e.g., 1,500x for MI Cancer Seek), supports over 100 biopharma partners like Moderna and Merck KGaA, and collaborates with 96 Caris Precision Oncology Alliance members, including 45 NCI-designated centers, to advance precision oncology research and drive superior clinical outcomes through innovative diagnostics and therapeutic discovery.
Initial Public Offering
The company launched its IPO on June 18th, 2025, under the ticker CAI and had sold approximately 297,109,837 shares at USD 17.00 (IPO price). We had covered this IPO in our ‘Kalkine IPO Report’ on June 16, 2025, and had concluded that this IPO was “Attractive” given it given the financial performance of the company, use of proceeds, and associated risks.
Conclusion
Caris Life Sciences (CAI), trading at $32.96 as of October 8, 2025, boasts a 93.88% gain from its $17.00 IPO price, offering a significant return for initial investors. However, this impressive growth is overshadowed by substantial risks. The company relies heavily on lab-developed tests (LDTs) that lack FDA authorization, posing a threat of costly regulatory compliance. Financially, over half of its Q1 2025 revenue comes from Medicare, exposing CAI to potentially margin-crushing policy shifts. Operationally, a rapid 31.4% increase in clinical cases is already straining infrastructure, risking bottlenecks. Given the confluence of regulatory, financial, and operational headwinds, investors who participated in the IPO may consider exiting their position at the $32.96 closing price on October 8, 2025.
*The reference data in this report has been partly sourced from Refinitiv.
Disclaimer This report has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine). Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.
Past performance is not a reliable indicator of future performance.
Please wait processing your request...